EA201891732A1 - Биспецифичные связывающие белки для pd-l1 и kdr - Google Patents

Биспецифичные связывающие белки для pd-l1 и kdr

Info

Publication number
EA201891732A1
EA201891732A1 EA201891732A EA201891732A EA201891732A1 EA 201891732 A1 EA201891732 A1 EA 201891732A1 EA 201891732 A EA201891732 A EA 201891732A EA 201891732 A EA201891732 A EA 201891732A EA 201891732 A1 EA201891732 A1 EA 201891732A1
Authority
EA
Eurasian Patent Office
Prior art keywords
binding proteins
bispecific binding
kdr
bispecific
human
Prior art date
Application number
EA201891732A
Other languages
English (en)
Inventor
Чжэньпин Чжу
Дан Лу
Original Assignee
Кадмон Корпорейшн, Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кадмон Корпорейшн, Ллк filed Critical Кадмон Корпорейшн, Ллк
Publication of EA201891732A1 publication Critical patent/EA201891732A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Предложены биспецифические связывающие белки, такие как биспецифические антитела, которые связываются и с PD-L1 человека, и с KDR человека. Указанные биспецифические связывающие белки эффективны для лечения заболеваний и состояний, характеризующихся иммуносупрессией и/или избыточным ангиогенезом.
EA201891732A 2016-02-02 2017-02-02 Биспецифичные связывающие белки для pd-l1 и kdr EA201891732A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662290350P 2016-02-02 2016-02-02
PCT/US2017/016230 WO2017136562A2 (en) 2016-02-02 2017-02-02 Bispecific binding proteins for pd-l1 and kdr

Publications (1)

Publication Number Publication Date
EA201891732A1 true EA201891732A1 (ru) 2019-02-28

Family

ID=59501012

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891732A EA201891732A1 (ru) 2016-02-02 2017-02-02 Биспецифичные связывающие белки для pd-l1 и kdr

Country Status (5)

Country Link
EP (1) EP3411068A4 (ru)
JP (1) JP2019506863A (ru)
CN (1) CN109310755A (ru)
EA (1) EA201891732A1 (ru)
WO (1) WO2017136562A2 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
WO2019042153A1 (zh) * 2017-09-01 2019-03-07 四川科伦博泰生物医药股份有限公司 重组双特异性抗体
KR102469248B1 (ko) 2018-02-28 2022-11-22 에이피 바이오사이언시스, 아이엔씨. 표적치료법을 위한 체크포인트 억제력을 갖는 이중작용성 단백질
JP2022507485A (ja) * 2018-11-16 2022-01-18 ヴァーチュオウソウ ビンコ，インク． Ｃｄ３８抗体とｉｃａｍ１抗体およびそれらの使用
CN111196855B (zh) * 2018-11-19 2022-11-15 三生国健药业（上海）股份有限公司 抗egfr/pd-1双特异性抗体
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体
WO2020114355A1 (en) * 2018-12-03 2020-06-11 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd Recombinant protein targeting pd-l1 and vegf
CN109776683B (zh) * 2019-03-19 2020-04-07 益科思特(北京)医药科技发展有限公司 一种双特异性抗体及其制备方法与应用
WO2020261093A1 (en) * 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
CN110563849B (zh) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd1双特异性抗体
JP7052149B2 (ja) * 2019-08-09 2022-04-11 安徽瀚海博▲シィン▼生物技▲シゥー▼有限公司 新型構造の抗ｖｅｇｆ－抗ｐｄ１二重特異性抗体
CN110498857B (zh) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd1双特异性抗体
CN110760517B (zh) * 2019-10-09 2022-04-29 天津大学 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN113754773A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pd1×pdl1的双特异性抗体
CN113754772A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pdl1×kdr的双特异性抗体
CN114106190A (zh) * 2020-08-31 2022-03-01 普米斯生物技术(珠海)有限公司 一种抗vegf/pd-l1双特异性抗体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514534B2 (en) * 2003-11-19 2009-04-07 Dyax Corp. Metalloproteinase-binding proteins
EP2064241B1 (en) * 2006-08-03 2015-10-07 Vaccinex, Inc. Anti-il-6 monoclonal antibodies and uses thereof
US7935345B2 (en) * 2007-05-21 2011-05-03 Children's Hospital & Research Center At Oakland Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use
CN103328632A (zh) * 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
BR112013027021A2 (pt) * 2011-04-19 2016-11-29 Merrimack Pharmaceuticals Inc anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
JP6138813B2 (ja) * 2011-11-28 2017-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗ｐｄ−ｌ１抗体及びその使用
WO2013181452A1 (en) * 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US20150238601A1 (en) * 2012-10-05 2015-08-27 Kadmon Corporation, Llc Treatment of ocular disorders
EP4116293A3 (en) * 2012-10-05 2023-03-29 Kadmon Corporation, LLC Rho kinase inhibitors
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
WO2015066543A1 (en) * 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
PT3094351T (pt) * 2014-01-15 2022-02-22 Kadmon Corp Llc Agentes imunomoduladores

Also Published As

Publication number Publication date
WO2017136562A2 (en) 2017-08-10
EP3411068A4 (en) 2020-01-29
JP2019506863A (ja) 2019-03-14
EP3411068A2 (en) 2018-12-12
CN109310755A (zh) 2019-02-05
WO2017136562A3 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EA201791485A1 (ru) Анти-cd47-антитела и их применения
NZ738008A (en) Tigit-binding agents and uses thereof
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA201891331A1 (ru) Бипаратопные полипептиды - антагонисты передачи сигнала wnt в опухолевых клетках
EA201791093A1 (ru) Антитела к cd47, способы и применение
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201691541A1 (ru) Новые анти-baff антитела
EA202091315A3 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201991546A1 (ru) Антигенсвязывающие белки против нейропилина и способы их применения
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
EA201890434A1 (ru) Антитела к cd154 и способы их применения